Immunotherapeutic approaches to treatment of fungal diseases

Darius Armstrong-James (Corresponding Author), Gordon D Brown, Mihai G Netea, Teresa Zelante, Mark S. Gresnigt , Frank L van de Veerdonk, Stuart M Levitz

Research output: Contribution to journalReview article

29 Citations (Scopus)
4 Downloads (Pure)

Abstract

Fungal infections cause morbidity worldwide and are associated with an unacceptably high mortality despite the availability of antifungal drugs. The incidence of mycoses is rising because of the HIV pandemic and because immunomodulatory drugs are increasingly used to treat autoimmune diseases and cancer. New classes of antifungal drugs have only been partly successful in improving the prognosis for patients with fungal infection. Adjunctive host-directed therapy is therefore believed to be the only option to further improve patient outcomes. Recent advances in the understanding of complex interactions between fungi and host have led to the design and exploration of novel therapeutic strategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viable adjuncts to existing antifungal regimens. In this report, we discuss immunotherapeutic approaches—the rationale behind their design, the challenges in their use, and the progress that is so urgently needed to overcome the devastating effect of fungal diseases.
Original languageEnglish
Pages (from-to)393-402
Number of pages10
JournalLancet Infectious Diseases
Volume17
Issue number12
Early online date31 Jul 2017
DOIs
Publication statusPublished - Dec 2017

Fingerprint

Mycoses
Pharmaceutical Preparations
Active Immunotherapy
Pandemics
Therapeutics
Immunotherapy
Autoimmune Diseases
Fungi
HIV
Cytokines
Morbidity
Mortality
Incidence
Neoplasms

Cite this

Armstrong-James, D., Brown, G. D., Netea, M. G., Zelante, T., Gresnigt , M. S., van de Veerdonk, F. L., & Levitz, S. M. (2017). Immunotherapeutic approaches to treatment of fungal diseases. Lancet Infectious Diseases, 17(12), 393-402. https://doi.org/10.1016/S1473-3099(17)30442-5

Immunotherapeutic approaches to treatment of fungal diseases. / Armstrong-James, Darius (Corresponding Author); Brown, Gordon D; Netea, Mihai G; Zelante, Teresa ; Gresnigt , Mark S. ; van de Veerdonk, Frank L; Levitz, Stuart M.

In: Lancet Infectious Diseases, Vol. 17, No. 12, 12.2017, p. 393-402.

Research output: Contribution to journalReview article

Armstrong-James, D, Brown, GD, Netea, MG, Zelante, T, Gresnigt , MS, van de Veerdonk, FL & Levitz, SM 2017, 'Immunotherapeutic approaches to treatment of fungal diseases', Lancet Infectious Diseases, vol. 17, no. 12, pp. 393-402. https://doi.org/10.1016/S1473-3099(17)30442-5
Armstrong-James D, Brown GD, Netea MG, Zelante T, Gresnigt MS, van de Veerdonk FL et al. Immunotherapeutic approaches to treatment of fungal diseases. Lancet Infectious Diseases. 2017 Dec;17(12):393-402. https://doi.org/10.1016/S1473-3099(17)30442-5
Armstrong-James, Darius ; Brown, Gordon D ; Netea, Mihai G ; Zelante, Teresa ; Gresnigt , Mark S. ; van de Veerdonk, Frank L ; Levitz, Stuart M. / Immunotherapeutic approaches to treatment of fungal diseases. In: Lancet Infectious Diseases. 2017 ; Vol. 17, No. 12. pp. 393-402.
@article{8803bbc52084409b90ffad299ba55427,
title = "Immunotherapeutic approaches to treatment of fungal diseases",
abstract = "Fungal infections cause morbidity worldwide and are associated with an unacceptably high mortality despite the availability of antifungal drugs. The incidence of mycoses is rising because of the HIV pandemic and because immunomodulatory drugs are increasingly used to treat autoimmune diseases and cancer. New classes of antifungal drugs have only been partly successful in improving the prognosis for patients with fungal infection. Adjunctive host-directed therapy is therefore believed to be the only option to further improve patient outcomes. Recent advances in the understanding of complex interactions between fungi and host have led to the design and exploration of novel therapeutic strategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viable adjuncts to existing antifungal regimens. In this report, we discuss immunotherapeutic approaches—the rationale behind their design, the challenges in their use, and the progress that is so urgently needed to overcome the devastating effect of fungal diseases.",
author = "Darius Armstrong-James and Brown, {Gordon D} and Netea, {Mihai G} and Teresa Zelante and Gresnigt, {Mark S.} and {van de Veerdonk}, {Frank L} and Levitz, {Stuart M}",
year = "2017",
month = "12",
doi = "10.1016/S1473-3099(17)30442-5",
language = "English",
volume = "17",
pages = "393--402",
journal = "Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "ELSEVIER APPL SCI PUBL LTD",
number = "12",

}

TY - JOUR

T1 - Immunotherapeutic approaches to treatment of fungal diseases

AU - Armstrong-James, Darius

AU - Brown, Gordon D

AU - Netea, Mihai G

AU - Zelante, Teresa

AU - Gresnigt , Mark S.

AU - van de Veerdonk, Frank L

AU - Levitz, Stuart M

PY - 2017/12

Y1 - 2017/12

N2 - Fungal infections cause morbidity worldwide and are associated with an unacceptably high mortality despite the availability of antifungal drugs. The incidence of mycoses is rising because of the HIV pandemic and because immunomodulatory drugs are increasingly used to treat autoimmune diseases and cancer. New classes of antifungal drugs have only been partly successful in improving the prognosis for patients with fungal infection. Adjunctive host-directed therapy is therefore believed to be the only option to further improve patient outcomes. Recent advances in the understanding of complex interactions between fungi and host have led to the design and exploration of novel therapeutic strategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viable adjuncts to existing antifungal regimens. In this report, we discuss immunotherapeutic approaches—the rationale behind their design, the challenges in their use, and the progress that is so urgently needed to overcome the devastating effect of fungal diseases.

AB - Fungal infections cause morbidity worldwide and are associated with an unacceptably high mortality despite the availability of antifungal drugs. The incidence of mycoses is rising because of the HIV pandemic and because immunomodulatory drugs are increasingly used to treat autoimmune diseases and cancer. New classes of antifungal drugs have only been partly successful in improving the prognosis for patients with fungal infection. Adjunctive host-directed therapy is therefore believed to be the only option to further improve patient outcomes. Recent advances in the understanding of complex interactions between fungi and host have led to the design and exploration of novel therapeutic strategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viable adjuncts to existing antifungal regimens. In this report, we discuss immunotherapeutic approaches—the rationale behind their design, the challenges in their use, and the progress that is so urgently needed to overcome the devastating effect of fungal diseases.

U2 - 10.1016/S1473-3099(17)30442-5

DO - 10.1016/S1473-3099(17)30442-5

M3 - Review article

VL - 17

SP - 393

EP - 402

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

SN - 1473-3099

IS - 12

ER -